Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:MTSR NASDAQ:PCVX NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$70.57-0.9%$77.65$69.12▼$118.21$4.93B0.141.02 million shs943,059 shsMTSRMetsera$34.89+5.8%$32.59$12.30▼$47.40$3.47BN/A1.03 million shs2.06 million shsPCVXVaxcyte$33.02-2.7%$34.44$27.66▼$121.06$4.38B1.211.17 million shs1.11 million shsPHVSPharvaris$20.00+0.6%$18.74$11.51▼$26.33$1.04B-2.81198,380 shs145,311 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus-0.87%-3.24%-11.37%-35.10%-32.68%MTSRMetsera+5.76%-13.79%+20.89%+36.02%+3,488,999,900.00%PCVXVaxcyte-2.74%-9.86%-0.75%-6.70%-58.14%PHVSPharvaris+0.60%-3.01%+12.23%+8.87%+16.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLNTHLantheus4.6154 of 5 stars3.43.00.04.23.32.51.9MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.3924 of 5 stars3.62.00.00.03.51.70.0PHVSPharvaris1.706 of 5 stars3.52.00.00.02.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.83Moderate Buy$131.2085.91% UpsideMTSRMetsera 3.00Buy$55.0057.64% UpsidePCVXVaxcyte 3.10Buy$136.50313.39% UpsidePHVSPharvaris 3.00Buy$36.2081.00% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, LNTH, PCVX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform6/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/11/2025PHVSPharvarisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$32.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/5/2025PHVSPharvarisWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.005/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.53B3.18$7.04 per share10.03$15.65 per share4.51MTSRMetseraN/AN/AN/AN/A$4.28 per shareN/APCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/APHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$312.44M$3.5220.0511.18N/A16.55%36.99%20.55%8/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)PHVSPharvaris-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)Latest PHVS, LNTH, PCVX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025PHVSPharvaris-$0.87N/AN/AN/AN/AN/A8/6/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A8/5/2025Q2 2025PCVXVaxcyte-$1.12N/AN/AN/AN/AN/A7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/A5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.495.745.46MTSRMetseraN/A5.266.55PCVXVaxcyteN/A17.7017.70PHVSPharvarisN/A11.1011.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%MTSRMetseraN/APCVXVaxcyte96.78%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipLNTHLantheus1.50%MTSRMetseraN/APCVXVaxcyte3.10%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus70069.19 million68.15 millionOptionableMTSRMetsera81105.06 millionN/AN/APCVXVaxcyte160129.00 million125.01 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionablePHVS, LNTH, PCVX, and MTSR HeadlinesRecent News About These CompaniesPharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Buy" by BrokeragesJuly 31 at 4:43 AM | marketbeat.comPharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutionsJuly 27, 2025 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's What HappenedJuly 26, 2025 | marketbeat.comPharvaris secures $175 million public offeringJuly 25, 2025 | thepharmaletter.comTPharvaris shares slide following $175 million equity offeringJuly 25, 2025 | msn.comPharvaris Raises $201 Million in Successful OfferingJuly 24, 2025 | tipranks.comPharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedJuly 24, 2025 | marketbeat.comPharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsJuly 22, 2025 | globenewswire.comPharvaris Announces Proposed Public Offering of Ordinary SharesJuly 22, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Pharvaris (PHVS)July 17, 2025 | theglobeandmail.comPharvaris (NASDAQ:PHVS) Stock Price Down 5.9% - Here's What HappenedJuly 15, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?July 14, 2025 | marketbeat.comBank of America Securities Reaffirms Their Sell Rating on Pharvaris (PHVS)July 12, 2025 | theglobeandmail.comPharvaris (NASDAQ:PHVS) Reaches New 1-Year High - Here's What HappenedJuly 12, 2025 | marketbeat.comPharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 ...July 11, 2025 | morningstar.comMPharvaris Updates Timing of Topline Data ... - The Manila TimesJuly 11, 2025 | manilatimes.netMPharvaris (NASDAQ:PHVS) Stock Price Up 9.9% - Time to Buy?July 11, 2025 | marketbeat.comPharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025July 10, 2025 | globenewswire.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from BrokeragesJuly 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?July 3, 2025 | marketbeat.comPharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National SummitJune 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, LNTH, PCVX, and MTSR Company DescriptionsLantheus NASDAQ:LNTH$70.57 -0.62 (-0.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$70.74 +0.17 (+0.23%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Metsera NASDAQ:MTSR$34.89 +1.90 (+5.76%) As of 08/1/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Vaxcyte NASDAQ:PCVX$33.02 -0.93 (-2.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$32.91 -0.11 (-0.33%) As of 08/1/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Pharvaris NASDAQ:PHVS$20.00 +0.12 (+0.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.08 +0.07 (+0.37%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
